JHL Biotech, Inc. has announced a signing of a Master Service Agreement (“MSA”) with Adimmune Corporation, a Taiwanese vaccine company, to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.

In full support of the Taiwan Government’s diligence and awareness for Covid-19 prevention, as well as to ensure abundant vaccine doses for the Taiwanese population, Adimmune has been continually searching for qualified partners for commercial production of antigens, which led to a collaboration with JHL.

Furthermore, since this pandemic is directly related to public health and national security, Adimmune and JHL are taking the opportunity to further build on a promising foundation by unifying locally developed production and supply chains to strengthen Taiwan’s biotech industry overall.

This development and manufacturing agreement was initiated and advocated by James Huang, the Executive Chairman and CEO of JHL Biotech, and Chi-Hsien Chan, M.D., the Chairman and CEO of Adimmune.

In order to support Taiwan’s already successful pandemic response initiative, Adimmune is currently collaborating with established companies such as JHL Biotech and continues to look for potential partners to further guarantee vaccine supply, for not only the Taiwanese people, but for other nations in need as well.